Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer Kailera Therapeutics today announced the appointment of Jamie Coleman, former U.S. Brand Leader for Zepbound, as Chief Commercial Officer.

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531 Kailera and Hengrui Pharma announced positive topline data from the 8 mg dose of Hengrui’s Phase 2 clinical trial of HRS9531, a GLP-1/GIP dual agonist.

Global Glucagon-like Peptide 1 (GLP-1) Market Soars to $18.75 Billion by 2023, Fueled by Increasing Healthcare Expenditure and Aging Population Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Global Glucagon-like Peptide 1 (GLP-1) Market (by Product, Route of Administration, & Region): Insights and Forecast with Potential Impact of...